# Moderna, Inc.: mRNA Biotech Case Study

A comprehensive biotechnology internship case study analyzing **Moderna, Inc.**, a pioneering mRNA therapeutics company. This project explores Moderna's technology, key products, respiratory vaccines portfolio, market impact, financial performance, and future initiatives through a professional slide deck.

## Table of Contents

1. [Overview](#overview)
2. [Slide Deck Highlights](#slide-deck-highlights)
3. [Visuals & Graphics](#visuals--graphics)
4. [Key Insights](#key-insights)
5. [Technologies & Tools](#technologies--tools)
6. [Future Work](#future-work)
7. [References](#references)

## Overview

- **Founded:** 2010, Cambridge, MA  
- **CEO:** Stéphane Bancel  
- **Employees:** ~5,800 (2024)  
- **Mission:** Develop RNA-based therapeutics and vaccines for infectious diseases, cancer, and rare diseases.

This case study examines Moderna's mRNA platform, product pipeline, respiratory vaccines, market impact, challenges, financial performance, and future strategies. It highlights how mRNA technology has revolutionized vaccine development and the challenges of sustaining growth in a post-pandemic market.

## Slide Deck Highlights

- **Company Overview:** Key milestones and growth trajectory.  
- **Technology & Innovation:** mRNA platform, mechanism, advantages, and funding sources.  
- **Key Products & Pipeline:** FDA-approved vaccines and candidates in development.  
- **Respiratory Vaccines Portfolio:** COVID-19, RSV, influenza, and combination vaccines.  
- **Market Impact:** Revenue trends, market share, and global distribution.  
- **Challenges & Competition:** Revenue volatility, patent disputes, manufacturing logistics, and competitors.  
- **Financial Performance & Strategy:** Revenue, net loss, cost reduction, and cash reserves.  
- **Future Outlook & Initiatives:** Pipeline expansion, manufacturing innovations, and global partnerships.  
- **Conclusion:** Summary of Moderna’s achievements, challenges, and potential future growth.

## Visuals & Graphics

- mRNA molecule diagram  
- Product pipeline charts (approved, late-stage, early-stage candidates)  
- Revenue, market share, and expense charts (bar, line, pie)  
- Infographics: company milestones, challenges vs. solutions, future roadmap  

## Key Insights

- Moderna’s mRNA platform enabled rapid vaccine development during COVID-19.  
- Revenue peaked at $19.3B in 2022, then declined to $3.2B in 2024 post-pandemic.  
- Competitive landscape includes Pfizer/BioNTech, GSK, Sanofi, CureVac.  
- Future growth relies on pipeline diversification (influenza, cancer, combination vaccines) and manufacturing efficiency.

## Technologies & Tools

- **Presentation Tools:** PowerPoint / Google Slides  
- **Data Visualization:** Charts, infographics, and pipeline diagrams  
- **Design:** Modern dark-blue + white theme for clarity and professionalism

## Future Work

- Expand slide deck with interactive visualizations  
- Incorporate updated financial and clinical trial data  
- Explore emerging mRNA applications beyond vaccines

## References

1. Moderna. (2025). *Annual Report*.  
2. FDA approvals: Spikevax and mRESVIA documents.  
3. Financial data: Q2 2025 earnings release.  
4. News & research articles (2020–2025).  

---

**License:** MIT License  
